56. Behcet disease
68 clinical trials,   87 drugs   (DrugBank: 31 drugs),   36 drug target genes,   113 drug target pathways

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03371095
(ClinicalTrials.gov)
March 15, 20187/12/2017Induction Therapy With Anti-TNFa vs Cyclophosphamide in Severe Behçet DiseaseMulticenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFa vs Cyclophosphamide in Severe Behçet DiseaseBehcet's Disease;VasculitisDrug: Infliximab;Drug: CyclophosphamideAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting12 YearsN/AAll52Phase 3NULL
2EUCTR2017-002264-41-FR
(EUCTR)
19/07/2017NA Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Infliximab to that of Cyclophosphamide in severe Behçet's disease - ITAC Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease
MedDRA version: 20.0;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000017240 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNA Female: yes
Male: yes
52Phase 2France